About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Understanding the Link Between Triple Negative Breast Cancer and Immunotherapy

by Dr. Trupti Shirole on December 15, 2016 at 3:59 PM
Font : A-A+

 Understanding the Link Between Triple Negative Breast Cancer and Immunotherapy

Triple negative breast cancer is so called because it lacks molecular characteristics that are associated with response to modern targeted treatments.

Christos Hatzis of Yale University, New Haven, CT, USA and colleagues have described a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease has been described

Advertisement


Hatzis and colleagues selected individual tumors from patients who had exhibited either good or poor sensitivity to cytotoxic chemotherapy, and characterized 29 cases of the disease by whole exome sequencing, with validation in further groups of patients.

Patients with a newly-defined "BRCA deficient" subtype experienced better survival with chemotherapy, and had a higher burden of mutations and neoantigens that could be targeted by the immune system. Based on these findings, the authors suggest that immunotherapies might be tested in patients with BRCA deficient, triple negative breast cancer.
Advertisement

In a commissioned Perspective article, Mack Su and David Fisher of Massachusetts General Hospital, Boston, MA, USA discuss developments in cancer immunotherapy, an area which has had a long history. During the past decade there have been notable advances in the treatment of melanoma, an aggressive tumor type which is increasing in incidence in some populations.

Alongside development of drugs which target the BRAF mutations that are common in melanoma, therapies have been discovered that stimulate the immune response to tumors - blocking so-called checkpoints, or inhibitors of the immune response. Su and Fisher describe the potential for use of different combinations of immune and targeted therapies and conclude that, as new immunotherapies are developed and tested in different tumor types, "deeper mechanistic insight will be required to inform clinical decisions."

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Organ Donation Week 2022 - 'Take the Pledge to Save Lives'
Test your Knowledge on Heart Transplantation
Test Your Knowledge on Lung Transplantation
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Women and Cancer Breast Biopsy Pagets disease of the breast Mastitis Cancer and Homeopathy Breast Cancer Facts Cancer Facts Cancer Tattoos A Body Art Breasts - Structures and Types 

Most Popular on Medindia

Sinopril (2mg) (Lacidipine) Find a Hospital Pregnancy Confirmation Calculator Color Blindness Calculator Nutam (400mg) (Piracetam) Noscaphene (Noscapine) A-Z Drug Brands in India Loram (2 mg) (Lorazepam) Sanatogen Vent Forte (Theophylline)
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use